Keep an Eye on Wednesday – GW’s Big Day With The FDA

Keep an Eye on Wednesday – GW’s Big Day With The FDA

Report… Barring an unexpected decision from the FDA, GW Pharma, which will hear from the agency by Wednesday, will make history this week when it receives approval for Epidiolex, its oral CBD solution that treats the seizures caused by rare forms of epilepsy....
GW Shares Gained 21% in May

GW Shares Gained 21% in May

Here’s the introduction to their piece.. anybody following the market will know that FDA approval is pending and the company are very active in medical states around the US   Why Marijuana Stock GW Pharmaceuticals Gained 21% in May What GW Pharmaceuticals...
The Lancet Publishes GW’s Phase 3  Epidiolex Results

The Lancet Publishes GW’s Phase 3 Epidiolex Results

Bezinga reports…… The piece in question featured results from GW Pharmaceuticals PLC- ADR GWPH 2.22% and Greenwich Biosciences’ Phase 3 study of Epidiolex — an oral cannabidiol solution — in patients with treatment-resistant Lennox-Gastaut syndrome, or...